Hugh McMillan

Professor, Department of Pediatrics, University of Ottawa

Pediatric Neurologist and Neuromuscular specialist at the Children’s Hospital of Eastern Ontario

Email Hugh

Dr. McMillan is a Pediatric Neurologist with specialization in Clinical Neurophysiology and Neuromuscular medicine at the Children’s Hospital of Eastern Ontario. He is a Professor in the Department of Pediatrics, Faculty of Medicine at the University of Ottawa.  He holds a Clinical Research Chair (Level 2) at the University of Ottawa and is a Clinical Investigator at the CHEO Research Institute

He has been an author of over 125 publications in peer-review journals and was a co-editor of a Pediatric Electromyography textbook.  He is also a leader in clinical and translational research in pediatric neurology & neuromuscular medicine.

Dr. McMillan completed a Neuromuscular and Neurophysiology Fellowship at Boston Children’s Hospital, Harvard University and the Lahey Clinic, Tufts University; a Pediatric Neurology Residency at the Children’s Hospital of Eastern Ontario, University of Ottawa and a Pediatric Residency at McMaster Children’s Hospital, McMaster University.

Dr. Hugh McMillan profile picture.

Read more about Hugh

Academic web profile
ORCiD profile

Recent publications

Poulin, KL, René, CA, Smith, IC, Vacratsis, PO, Burger, D, McMillan, HJ et al.. Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy. Mol Ther Adv. 2026.34 (2)201757 PMID:42232219

McMillan, HJ, Oskoui, M. Predicting Functional Decline in Duchenne Muscular Dystrophy: Advancing Trial Readiness and Patient Counseling. Neurology. 2026.106 (12)e214882 PMID:42190149

Wood, CL, Babalola, F, Benjamin, RW, Lam, C, McAdam, L, Nicolau, S et al.. Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle Nerve. 2026. PMID:42178495

Guridi, M, De Ford, C, See, CG, Murphy, AP, Chen, Y, Scharke, M et al.. Assessing biomarkers of bone metabolism and the role of the interleukin-6 signaling pathway in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2026.62 106414 PMID:41894885

Sbrocchi, AM, Kinnett, K, Lautatzis, ME, McMillan, HJ, Selby, KA, Veerapandiyan, A et al.. Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. J Endocr Soc. 2026.10 (2)bvaf181 PMID:41509125

Osman, H, Adamji, Z, Lintern, S, Smith, IC, Grant, A, Lessard, LER et al.. Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives. Health Expect. 2025.28 (6)e70529 PMID:41405177

Ahmadiharchegani, F, Tobin, RA, Degan, C, Naveed, A, Guglieri, M, Jiménez-Requena, A et al.. Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients. Sci Rep. 2025.15 (1)39997 PMID:41238663

Proud, CM, Kichula, EA, Matesanz, SE, Kumar, A, Saito, K, Laverty, CG et al.. Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations. J Neuromuscul Dis. 2025. 22143602251391258 PMID:41212681

Dussah, N, McKim, DA, Mah, JK, McMillan, HJ, Campbell, C, Bijelić, V et al.. Patterns of Adherence to Lung Volume Recruitment Therapy Amongst Individuals With Duchenne Muscular Dystrophy: A Secondary Analysis of the STEADFAST Randomized Controlled Trial. Pediatr Pulmonol. 2025.60 (10)e71357 PMID:41147267

Phung, K, Rauch, D, Jackowski, S, Scharke, M, Koujok, K, Matzinger, MA et al.. Automated bone age calculation is an independent predictor of vertebral fracture burden in Duchenne muscular dystrophy. Osteoporos Int. 2025.36 (11)2287-2297 PMID:41120763

See more on PubMed